- Celldex Therapeutics ( NASDAQ: CLDX ) said the first patient was dosed in a phase 2 trial of barzolvolimab to treat the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD).
- Hives, also known a urticaria, is a skin reaction which causes itchy welts. ColdU symptoms include itching, burning wheals and angioedema when skin is exposed to temperatures below skin temperature. While, SD symptoms include development of wheals and flare reaction in response to scratching or rubbing of the skin.
- The company said the study will evaluating the efficacy and safety of multiple doses of barzolvolimab — a monoclonal antibody — in patients with CIndU who remain symptomatic despite antihistamine therapy and in patients with CIndU who remain symptomatic despite antihistamine therapy, to determine the optimal dose.
- The trial is expected to enroll ~180 patients.
- Earlier in July, the company reported data from a phase 1b study of barzolvolimab in patients with chronic spontaneous urticaria.
For further details see:
Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder